Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
8-K/A
Financial Statements and Exhibits
19 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
8-K
Departure of Directors or Certain Officers
3 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
29 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
DEFM14C
Information related to merger
5 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
PREM14C
Preliminary information related to merger
20 Feb 24
8-K
Unregistered Sales of Equity Securities
9 Feb 24
8-K
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
6 Feb 24
8-K/A
Consolidated Financial Statements
3 Jan 24
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
D
$433.83 k in equity / securities to be acquired / Shares of common stock, sold $433.83 k, 3 investors
2 Nov 23
8-K
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
20 Oct 23
8-K
Entry into a Material Definitive Agreement
21 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
1 Aug 23
DEF 14A
Definitive proxy
23 Jun 23
10-Q
2023 Q1
Quarterly report
23 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Changes in Registrant's Certifying Accountant
7 Apr 23
8-K/A
Index to Financial Statements
6 Apr 23
10-K
2022 FY
Annual report
9 Feb 23
NT 10-K
Notice of late annual filing
30 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
30 Jan 23
8-K
Completion of Acquisition or Disposition of Assets
25 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jan 23
425
Business combination disclosure
12 Jan 23
Latest ownership filings
4
Change in insider ownership
6 Mar 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
4
Change in insider ownership
12 Feb 24
SC 13D/A
Israel Biotech Fund I, L.P.
12 Feb 24
SC 13G/A
Schindel Yair Chaim
12 Feb 24
4
Change in insider ownership
21 Nov 23
SC 13D/A
Israel Biotech Fund I, L.P.
21 Nov 23
3
Yuval Cabilly
8 Nov 23
3/A
Roy Golan
3 Nov 23
3/A
Pini Orbach
3 Nov 23
3/A
Bridget A Martell
3 Nov 23
4
Change in insider ownership
31 Oct 23
SC 13D/A
Israel Biotech Fund I, L.P.
31 Oct 23
SC 13G/A
Schindel Yair Chaim
23 Oct 23
4
Change in insider ownership
23 Oct 23
4/A
Change in insider ownership (amended)
29 Sep 23
3/A
Initial statement of insider ownership (amended)
29 Sep 23
4
Change in insider ownership
11 Sep 23
3
Initial statement of insider ownership
11 Sep 23
SC 13D
Israel Biotech Fund I, L.P.
11 Sep 23
SC 13G
Redmile Group, LLC
8 Feb 23
3
Yair Chaim Schindel
30 Jan 23
SC 13G
Schindel Yair Chaim
30 Jan 23
4
DAVID SIDRANSKY
23 Jan 23
4
MURRAY A GOLDBERG
23 Jan 23
4
Vered Bisker-Leib
23 Jan 23
4
Robert J. Spiegel
23 Jan 23
3
MURRAY A GOLDBERG
23 Jan 23
3
Vered Bisker-Leib
23 Jan 23
3
Robert J. Spiegel
23 Jan 23
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 22
3
Igor Gitelman
16 Feb 21
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
11 Feb 21
SC 13G
Lincoln Park Capital Fund, LLC
3 Aug 20
4
Molly Henderson
5 May 20
4
Samir N Khleif
5 May 20
4
RONI APPEL
5 May 20
4
Kenneth A Berlin
5 May 20
4
JAMES P PATTON
5 May 20